Diplomat Pharmacy (DPLO) Coverage Initiated at Lake Street Capital

Investment analysts at Lake Street Capital initiated coverage on shares of Diplomat Pharmacy (NYSE:DPLO) in a note issued to investors on Friday. The brokerage set a “buy” rating and a $35.00 price target on the stock. Lake Street Capital’s price objective indicates a potential upside of 46.69% from the stock’s current price.

A number of other research analysts have also issued reports on DPLO. BidaskClub lowered shares of Diplomat Pharmacy from a “strong-buy” rating to a “buy” rating in a research note on Tuesday, October 17th. Mizuho set a $16.00 price target on shares of Diplomat Pharmacy and gave the stock a “hold” rating in a research note on Tuesday, October 24th. Leerink Swann boosted their price objective on shares of Diplomat Pharmacy from $16.00 to $20.00 and gave the stock a “market perform” rating in a report on Tuesday, November 7th. Needham & Company LLC boosted their price objective on shares of Diplomat Pharmacy from $23.75 to $24.00 and gave the stock a “buy” rating in a report on Wednesday, November 8th. Finally, Robert W. Baird downgraded shares of Diplomat Pharmacy from an “outperform” rating to a “neutral” rating and decreased their price objective for the stock from $24.00 to $18.00 in a report on Thursday, November 16th. Seven research analysts have rated the stock with a hold rating, four have assigned a buy rating and one has issued a strong buy rating to the company. The stock presently has an average rating of “Buy” and an average target price of $23.95.

Diplomat Pharmacy (NYSE:DPLO) opened at $23.86 on Friday. Diplomat Pharmacy has a one year low of $13.39 and a one year high of $27.78. The company has a current ratio of 1.34, a quick ratio of 0.82 and a debt-to-equity ratio of 0.18. The stock has a market cap of $1,667.42, a PE ratio of 238.60, a PEG ratio of 3.66 and a beta of 1.06.

In other Diplomat Pharmacy news, President Joel Saban purchased 10,000 shares of Diplomat Pharmacy stock in a transaction on Monday, November 20th. The shares were bought at an average price of $15.24 per share, with a total value of $152,400.00. Following the completion of the acquisition, the president now directly owns 12,000 shares of the company’s stock, valued at $182,880. The transaction was disclosed in a document filed with the SEC, which is available through this link. Also, Director Jeffrey G. Park purchased 3,000 shares of Diplomat Pharmacy stock in a transaction on Monday, November 20th. The stock was acquired at an average cost of $15.46 per share, for a total transaction of $46,380.00. Following the acquisition, the director now directly owns 7,640 shares of the company’s stock, valued at $118,114.40. The disclosure for this purchase can be found here. In the last three months, insiders have purchased 15,000 shares of company stock worth $228,780. 30.20% of the stock is owned by insiders.

Several hedge funds and other institutional investors have recently made changes to their positions in DPLO. Schwab Charles Investment Management Inc. lifted its holdings in shares of Diplomat Pharmacy by 40.4% in the second quarter. Schwab Charles Investment Management Inc. now owns 230,013 shares of the company’s stock valued at $3,405,000 after purchasing an additional 66,244 shares in the last quarter. Swiss National Bank lifted its holdings in shares of Diplomat Pharmacy by 21.0% in the second quarter. Swiss National Bank now owns 77,900 shares of the company’s stock valued at $1,153,000 after purchasing an additional 13,500 shares in the last quarter. Teachers Advisors LLC lifted its holdings in shares of Diplomat Pharmacy by 6.3% in the second quarter. Teachers Advisors LLC now owns 297,014 shares of the company’s stock valued at $4,396,000 after purchasing an additional 17,711 shares in the last quarter. TIAA CREF Investment Management LLC lifted its holdings in shares of Diplomat Pharmacy by 2.0% in the second quarter. TIAA CREF Investment Management LLC now owns 380,101 shares of the company’s stock valued at $5,625,000 after purchasing an additional 7,348 shares in the last quarter. Finally, Ameriprise Financial Inc. lifted its holdings in shares of Diplomat Pharmacy by 19.3% in the second quarter. Ameriprise Financial Inc. now owns 272,979 shares of the company’s stock valued at $4,043,000 after purchasing an additional 44,135 shares in the last quarter. 69.87% of the stock is currently owned by institutional investors.

TRADEMARK VIOLATION WARNING: “Diplomat Pharmacy (DPLO) Coverage Initiated at Lake Street Capital” was reported by American Banking News and is the sole property of of American Banking News. If you are viewing this report on another site, it was illegally copied and republished in violation of US and international copyright and trademark legislation. The correct version of this report can be viewed at https://www.americanbankingnews.com/2018/02/09/diplomat-pharmacy-dplo-coverage-initiated-at-lake-street-capital.html.

About Diplomat Pharmacy

Diplomat Pharmacy, Inc (Diplomat) operates a specialty pharmacy business, which stocks, dispenses and distributes prescriptions for various biotechnology and specialty pharmaceutical manufacturers. The Company operates through specialty pharmacy services segment. The Company’s primary focus is on medication management programs for individuals with chronic diseases, including oncology, immunology, hepatitis, multiple sclerosis, specialty infusion therapy, and various other serious and/or long-term conditions.

Analyst Recommendations for Diplomat Pharmacy (NYSE:DPLO)

Receive News & Ratings for Diplomat Pharmacy Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Diplomat Pharmacy and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply